Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
Clinical trial NCT04901416 · COMPLETED
Trial details
- NCT number
- NCT04901416
- Sponsor
- Coeptis Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-15
- Primary completion
- 2023-10-15
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.